Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report
Închide
Conţinutul numărului revistei
Articolul precedent
Articolul urmator
99 0
SM ISO690:2012
UŞURELU, Natalia, BLĂNIŢĂ, Daniela, BOICIUC, Chiril, HLISTUN, Victoria, EGOROV, Vladimir, POPOVICI, Eugen, GNATCOVA, Elena, STAMATI, Adela, OGLINDA, Ana, REVENCO, Ninel, GLADUN, Sergiu, TSURYA, Valentin. Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report. In: Medicine and Pharmacy Reports, 2021, vol. 94, supl. nr. 1, pp. 57-60. ISSN 2602-0807. DOI: https://doi.org/10.15386/mpr-2232
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Medicine and Pharmacy Reports
Volumul 94, Supliment nr. 1 / 2021 / ISSN 2602-0807 /ISSNe 2668-0572

Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report

DOI:https://doi.org/10.15386/mpr-2232

Pag. 57-60

Uşurelu Natalia1, Blăniţă Daniela1, Boiciuc Chiril1, Hlistun Victoria1, Egorov Vladimir1, Popovici Eugen1, Gnatcova Elena1, Stamati Adela2, Oglinda Ana2, Revenco Ninel21, Gladun Sergiu1, Tsurya Valentin21
 
1 Institute of Mother and Child,
2 ”Nicolae Testemițanu” State University of Medicine and Pharmacy
 
 
Disponibil în IBN: 9 aprilie 2024


Rezumat

We report on a case of a little girl patient diagnosed with Gaucher disease (GD) type 1 in her early childhood and our first experience with enzyme replacement therapy (ERT). She was first diagnosed accidentally with enlarged spleen during a pediatric examination when she was three years old, but the family ignored investigations; she was hospitalized for diagnosis at six years old. The GD was confirmed based on: clinical manifestations of left abdominal flank pain, multiple bruising, general weakness, bone pain, low appetite, failure to thrive <5th percentile, minor hepato- and severe splenomegaly, enlarged submaxillary lymph nodes, associated by anemia with normal platelets; low activity of beta-Glucosidase, two found mutations in GBA gene, Gaucher cells in bone marrow. The ERT was initiated with Imiglucerase (54 UI/kg/2 wks) two years later after diagnosis, avoiding the splenectomy. Subsequently, the platelets showed the first a promising result, gradually increasing their number every 2 weeks and maintaining it in good parameters till the reported moment (2.5 yrs from the start). The hemoglobin level was appreciated within normal ranges 3 months after ERT start and stabilized completely after 6 months. On the other hand, the red blood count normalized within 20 months of applied therapy. The Lyso-GL-1 decreased by 30% after three months of therapy, no antibodies to Imiglucerase were found. The initial spleen volume (1178.19 cm3) decreased by almost 60% in 6 months of ERT, reaching absolutely normal dimensions after 9 months. The ERT with Imiglucerase was tolerated very well by the patient, showing a clear improvement of clinical symptoms after 4–6 months of therapy, hematological picture and splenomegaly solving. Even if the little patient had to come every 2 weeks for infusion, her quality of life improved a lot, being a totally happy child, going to school and having friends. The ERT should be initiated immediately after diagnosis to prevent the multisystem complications.

Cuvinte-cheie
Gaucher disease, splenomegaly, Imiglucerase, ERT